中英文本內容如有差異或不一致，概以英文版本為準。 Zijin Gold International Company Limited 紫金黃金國際有限公司 （於2025年3月19日更改名稱） 之 組織章程細則 （經2025年9月17日通過的特別決議案採納） – 1 – 公司條例（第622章） 公眾股份有限公司 Zijin Gold International Company Limited 紫金黃金國際有限公司 （於2025年3月19日更改名稱） 之 組織章程細則 （經2025年9月17日通過的特別決議案採納） 引言 – 2 – 1. 章程細則範本不適用及強制性細則 (1)《公司（章程細則範本）公告》（2013年第77號法律公告）中附表1「公眾股份有限公 司的章程細則範本」中的規例將不適用於本公司。 (2) 本公司的名稱是紫金黃金國際有限公司(Zijin Gold International Company Limited)。 (3) 成員的法律責任屬有限。 (4) 成員的法律責任，是以成員所持有股份的未繳款額為限。 (1) 本章程細則內，除非文義另有所指外，下表第一欄所列詞彙具有各自對應的第 二欄所載涵義： ...

Summary of WuXi AppTec Conference Call Industry Overview - The ADC (Antibody-Drug Conjugate) industry is projected to maintain an annual growth rate of approximately 30%, significantly higher than that of chemical and biological drugs [2][4] - The global market has 16 ADC products launched, with rapid sales growth expected to continue [2][9] - The complexity of ADCs leads to a high outsourcing rate, currently around 70%, which is anticipated to rise to 80% [11] Company Insights - WuXi AppTec is a leader in the domestic market, benefiting from the rapid growth of the ADC industry [2] - The company possesses a unique CRDMO (Contract Research, Development, and Manufacturing Organization) strategy and core technologies, such as the Wuxi DIX toxin technology, enabling integrated production capabilities from small molecule toxins to antibody conjugation [4][5][6] - The company is constructing dual facilities to ensure supply chain stability and security [6] Financial Performance - In the first half of 2025, the number of ADC projects increased by 44% year-over-year, with the number of clients growing by 34% [3][15] - The backlog of orders reached $1.3 billion, reflecting a nearly 160% year-over-year increase [3][16] - The revenue contribution from backend services rose to 59%, up from approximately 30% previously [16] Growth Projections - Short-term growth is primarily driven by commercialized projects, with large-scale volume expected to begin in 2027 [7][17] - The company anticipates a growth rate of around 45% for 2025, although a conservative estimate of 35% has been provided by Zhongtai Securities [8][17] - The introduction of new molecules such as bispecific antibodies and XDCs is expected to drive future growth [7][10] Competitive Advantages - WuXi AppTec's competitive advantages include a comprehensive CRDMO service platform, deep industry experience since 2013, and a significant reduction in the drug development cycle from an average of 24-30 months to 15 months [13] - The company has expanded its production capacity significantly, with plans to triple its capacity by 2024, focusing on both domestic and international markets [14] Market Position - WuXi AppTec holds nearly 10% of the global market share and 70% of the domestic market share, indicating room for further growth [11][12] - The company’s integrated production capabilities position it favorably against competitors, enhancing customer loyalty and retention [13] Future Outlook - The company is optimistic about its long-term growth prospects, especially with the potential for increased revenue from clinical phase III projects [17] - The overall industry outlook remains positive, supporting sustained high growth for WuXi AppTec [17]

上周五下午17:00后各券商陆续公布三只新股的中签结果，但详细信息要等明天暗盘交易结束后，晚上22点港交所官方网站披露易发布的新股配发结果公 告。 | | 西普尼(02583.HK)-分配结果 | | | --- | --- | --- | | 定价 | HK$29.60 | | | 一手股数 | 100 | | | 一手市值 | HK$2960 | | | 申购股数(股) | 最小中签股数(股) | 最大中签股数() | | 甲组 | | | | 100-100,000 | 0 | 100 | | 乙组 | | | | 200,000 | 0 | 100 | | 300,000 | 100 | 200 | | 400,000 | 100 | 200 | | 530,000 | 100 | 200 | | | 仅供参考,详细结果可阅读港交所的通告! | | 西普尼以招股上限定价29.6港元，一手市值2960港元。甲组全部抽签，乙二才能稳中一手，申购顶头槌用10倍融资还需要158万本金，最多也就中签2手， 货值6000港元。 | | 博泰车联(02889.HK)-分配结果 | | | --- | --- | - ...

新华财经上海9月28日电（记者胡洁菲）近日，由药明合联举办的2025BPD（Biopharmaceutical BioprocessDevelopment）新加坡生物药工艺发展大会举办。 "新加坡基地是我们全球供应链布局的战略高地，其核心定位是服务海外商业化生产需求。"药明合联相 关负责人在大会期间表示。据介绍，该基地将复制公司无锡基地"All-In-One"的集成化能力，重点聚焦 后期商业化生产环节，与中国上海、无锡、常州三大基地形成功能互补的全球网络。这既考虑了海外客 户对供应链区域性的核心需求，也通过聚焦成熟工艺生产实现了效率最优化，即通过提升自动化水平与 发挥规模优势，确保海外基地达到与国内相当的运营效率与盈利水平。 "从整个药物偶联市场发展看，海外市场远远大于国内市场，同时，多区域供应链布局已成为全球生物 医药企业的核心需求，可以预见，未来药明合联在海外市场还将保持高速增长。"李锦才说，尽管面临 各类外部环境挑战，其北美市场仍实现强劲增长，2024年整体增速超90%。据透露，药明合联正积极评 估欧洲、美国等其他关键市场的布局机会，未来将根据区域执行力、监管环境、成本结构等多维度因素 推进全球产能网络 ...

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry [2] Core Insights - The CXO industry is experiencing a recovery in market conditions, driven by improvements in supply-demand dynamics and a rebound in financing activities for innovative drugs [3][4] - The CDMO sector continues to show high growth potential, with leading companies improving their performance and expanding into emerging markets [5][6] - The CRO sector is approaching a turning point, with signs of demand recovery and improved order conditions [6][7] Summary by Sections CXO Industry Overview - The CXO industry operates on a "water seller" business model, closely tied to the financing of the biopharmaceutical sector. In the first eight months of 2025, overseas innovative drug financing reached $22.6 billion, a year-on-year decline of approximately 36%, while domestic innovative drug financing amounted to $7.75 billion, a year-on-year increase of about 89% [3][31] - The leading companies in the CXO sector are expected to enter an expansion phase as demand recovers, while smaller companies may face increased competition and exit the market [4][44] CDMO Sector - CDMO leading companies have begun to see marginal improvements in performance since Q4 2024, attributed to high overseas revenue and a unique business model that supports project pipeline growth [5][46] - The order situation for CDMO companies has improved significantly, with notable increases in backlogged orders for major players like WuXi AppTec and WuXi Biologics [49][50] - The CDMO business model is characterized by strong customer retention and project scalability, allowing for sustained growth despite challenges in new project signings [52] CRO Sector - The CRO sector is witnessing a divergence in performance among leading companies, with some starting to recover. The overall order situation has shown improvement, indicating a potential demand revival [6][22] - The price increase of experimental monkeys suggests a forthcoming recovery in preclinical CRO demand, highlighting the importance of resource availability for leading CRO companies [6][24] - The integration of AI in drug development processes is expected to enhance efficiency and reduce costs, with many domestic CRO leaders already adopting AI technologies [7][18] Recommended Companies - The report suggests focusing on key players in the CXO sector, including WuXi AppTec, WuXi Biologics, WuXi AppTec, and others, which are positioned well for growth based on their business characteristics and market trends [8][10]

Group 1 - The IPO of Zijin Gold International has been postponed to September 25 due to severe weather conditions in Hong Kong caused by a typhoon, with Morgan Stanley and CITIC Securities as joint sponsors [1] - As of September 25, the brokers have lent out HKD 480.7 billion in margin financing, with the public offering subscription amounting to HKD 24.98 billion, resulting in an oversubscription of 191.4 times [1] - Zijin Gold International plans to issue 350 million shares, with 10% allocated for public offering at a price of HKD 71.59 per share, aiming to raise HKD 24.98 billion [1] Group 2 - Qualified H-share shareholders of Zijin Mining will have priority to subscribe to 17.45 million reserved shares of Zijin Gold International, representing 5% of the total shares available for subscription [2] - Zijin Mining is not only the major shareholder of Zijin Gold International but also its largest customer and main supplier, with a net payable amount of USD 640 million as of June 30, 2025 [2] - In the previous year, Zijin Gold International reported revenues of USD 2.99 billion, a year-on-year increase of 32.2%, and a net profit attributable to shareholders of USD 480 million, up 108.9% [2] Group 3 - The net proceeds from the IPO will be allocated as follows: approximately 33.4% for settling the acquisition cost of the Raygorodok gold mine in Kazakhstan, 50% for upgrading and construction projects at existing mines, 6.5% for exploration activities, and 10% for general corporate purposes [3]

Core Viewpoint - The IPO of Zijin Gold International has been delayed due to severe weather conditions in Hong Kong, with significant oversubscription and strong backing from cornerstone investors [1][2]. Group 1: IPO Details - The IPO subscription deadline has been postponed from September 24 to September 25, with a total of HKD 480.7 billion in margin loans extended by brokers, resulting in an oversubscription rate of 191.4 times against the public offering amount of HKD 2.498 billion [1]. - Zijin Gold International plans to issue 350 million shares at a price of HKD 71.59 per share, aiming to raise HKD 24.98 billion, with the listing expected on September 30 [1]. - The company has secured full subscription for its international placement, with 28 cornerstone investors committing approximately USD 1.6 billion, representing 49.9% of the global offering [1]. Group 2: Company Background - Zijin Gold International is a spin-off from Zijin Mining Group, primarily engaged in gold exploration, mining, refining, and sales, with operations in Central Asia, South America, Oceania, and Africa [2]. - As of June 30, 2025, the net amount payable to Zijin Mining by Zijin Gold International is USD 640 million, highlighting the close relationship between the two entities [2]. - In the previous year, Zijin Gold International reported revenues of USD 2.99 billion, a year-on-year increase of 32.2%, with a net profit attributable to shareholders of USD 480 million, up 108.9% [2]. Group 3: Use of Proceeds - Approximately 33.4% of the net proceeds from the IPO will be used to settle the acquisition cost of the Raygorodok gold mine in Kazakhstan, while 50% will be allocated for upgrades and construction projects at existing mines to enhance production capacity [3]. - 6.5% of the funds will be directed towards exploration activities to fully realize growth potential, and 10% will be used for general corporate purposes [3].

Core Insights - Three companies, Zijin Gold International, Sipni, and Botai Che Lian, are currently in the process of public offerings, with significant oversubscription rates indicating strong investor interest [1] Group 1: Zijin Gold International (02259) - Total amount borrowed by brokers for Zijin Gold International is 4640.806 million HKD, with an oversubscription rate exceeding 184 times [1][2] - The total fundraising amount for Zijin Gold International is 2.498 billion HKD [2] Group 2: Sipni (02583) - Total amount borrowed by brokers for Sipni is 588.3228 million HKD, with an oversubscription rate exceeding 1896 times [1][2] - The total fundraising amount for Sipni is 0.31 billion HKD [2] Group 3: Botai Che Lian (02889) - Total amount borrowed by brokers for Botai Che Lian is 245.2006 million HKD, with an oversubscription rate exceeding 228 times [1][3] - The total fundraising amount for Botai Che Lian is 1.07 billion HKD [3]

根据弗若斯特沙利文的资料，紫金黄金国际截至2024年12月31日的黄金储量和2024年的黄金产量分别位 居全球第九和第十一。2022年至2024年黄金产量的复合年增长率达到21.4%，母公司拥有人应占净利润 的复合年增长率为61.9%。 紫金黄金国际预期，集资款项所得用作支付收购哈萨克斯坦Raygorodok金矿的款项；未来五年内升级及 建设现有矿山，全面提升产能；用于营运的所有矿山的勘探活动；及一般公司用途。 紫金矿业 紫金矿业 分时图 日K线 周K线 月K线 25.93 0.11 0.43% 1.20% 0.81% 0.39% 0.00% 0.39% 0.81% 1.20% 25.51 25.61 25.72 25.82 25.92 26.03 26.13 09:30 10:30 11:30/13:00 14:00 15:00 0 135万 269万 404万 紫金黄金国际(02259)于9月19日起至24日招股，预期9月29日挂牌。不过，面对超强台风"桦加沙"迫近 香港，紫金黄金国际或要推迟认购期以至挂牌日期。 目前，天文台于9月23日(周二)下午2时20分改发8号烈风或暴风信号，并会考虑桦加沙与香港的 ...

智通财经APP获悉，紫金黄金国际(02259)、西普尼(02583)、博泰车联(02889)正在招股中。截止9月23 日，富途、辉立、耀才等券商合计为紫金黄金借出1872.859亿港元，超购逾73倍；合计为西普尼借出 154.8279亿港元，超购逾498倍；合计为博泰车联借出22.5086亿港元，超购逾20倍。 | 新股 | 券商 | 仔展(亿元) | 自率(%) | | --- | --- | --- | --- | | | 富途 | 906.90 | 0.00 | | | 辉立 | 503.00 | 0.00 | | | 耀才 | 90.00 | 0.00 | | | 安盛 | 40.80 | 0.00 | | 紫金黄金国际 | 信诚 | 60.00 | 0.00 | | (02259) | 宮立 | 13.79 | 0.00 | | | 时富 | 2.80 | 0.00 | | | 其他总和 | 255.569 | | | | 共计 | 1872.859 | | | | | 集资额:24.98亿元 | | | | | 认购:超购逾73倍 | | | | 富途 | 91.57 | 0.00 | | | 辉 ...